Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

800 kids monitored for arthritis drug risks over years

NCT ID NCT01357668

Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 800 children with juvenile idiopathic arthritis who are taking or have taken abatacept. Researchers track serious infections, autoimmune problems, and cancer risks over the long term to better understand the drug's safety. No new treatments are tested—this is an observational registry to gather real-world data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2013

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric rheumatology clinics

Ages

Up to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria * Diagnosis of JIA (any subtype) * Age \< 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept * Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial * Parent or legally acceptable representative willing to participate in the study and sign the informed consent Exclusion Criteria * Pregnant or nursing female at the time of enrollment * Prior malignancies if the patient has not been malignancy free for at least 5 years. * Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study * Known poor compliance with clinic visits (based on physician judgment).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile idiopathic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile idiopathic arthritis

Contacts and locations

Locations

  • Local Institution

    Moscow, 119991, Russia

  • Local Institution - 0001

    Princeton, New Jersey, 08540, United States

  • Local Institution - 0002

    Innsbruck, A-6020, Austria

  • Local Institution - 0003

    Bad Bramstedt, 24576, Germany

  • Local Institution - 0004

    Barcelona, 08035, Spain

  • Local Institution - 0005

    Paris, 75743, France

  • Local Institution - 0006

    Guadalajara, Jalisco, 44620, Mexico

  • Local Institution - 0007

    Lima, 1, Peru

  • Local Institution - 0009

    Pretoria, Gauteng, 0002, South Africa

  • Local Institution - 0010

    Botucatu, São Paulo, 18618-970, Brazil

  • Local Institution - 0011

    Montreal, Quebec, H4A 3J1, Canada

  • Local Institution - 0012

    Copenhagen, 2100, Denmark

  • Local Institution - 0013

    Bristol, BS2 8BJ, United Kingdom

  • Local Institution - 0014

    Jerusalem, 91031, Israel

  • Local Institution - 0015

    Genova, 16147, Italy

  • Local Institution - 0016

    Thessaloniki, 54642, Greece

  • Local Institution - 0017

    Budapest, H-1023, Hungary

  • Local Institution - 0018

    Riga, LV-1007, Latvia

  • Local Institution - 0019

    Utrecht, 3584 EA, Netherlands

  • Local Institution - 0020

    Lisbon, 1600, Portugal

  • Local Institution - 0021

    Cluj-Napoca, 0, Romania

  • Local Institution - 0022

    Piešťany, 0, Slovakia

  • Local Institution - 0023

    Bayamón, PR 960, Puerto Rico

  • Local Institution - 0024

    Riyadh, 11426, Saudi Arabia

  • Local Institution - 0025

    Bregenz, 0, Austria

  • Local Institution - 0026

    Campinas, São Paulo, 13083-888, Brazil

  • Local Institution - 0027

    Rio de Janeiro, 22250-110, Brazil

  • Local Institution - 0028

    São Paulo, São Paulo, 04023-061, Brazil

  • Local Institution - 0029

    Calgary, Alberta, T3B 6A8, Canada

  • Local Institution - 0030

    Berlin, 10117, Germany

  • Local Institution - 0031

    Hamburg, 22391, Germany

  • Local Institution - 0032

    Vienna, 1160, Austria

  • Local Institution - 0033

    Heidelberg, 69120, Germany

  • Local Institution - 0034

    Freiburg im Breisgau, 79106, Germany

  • Local Institution - 0035

    Aarhus, Central Jutland, 8200, Denmark

  • Local Institution - 0036

    Sant Joan Despí, Barcelona, 08970, Spain

  • Local Institution - 0037

    Murcia, 30120, Spain

  • Local Institution - 0038

    Madrid, 28046, Spain

  • Local Institution - 0039

    Valencia, 46009, Spain

  • Local Institution - 0040

    Clermont-Ferrand, Puy-de-Dôme, 63000, France

  • Local Institution - 0041

    Toulouse, 31059, France

  • Local Institution - 0042

    Florence, 50139, Italy

  • Local Institution - 0043

    Naples, 80131, Italy

  • Local Institution - 0044

    Padova, 35128, Italy

  • Local Institution - 0045

    Naples, 80138, Italy

  • Local Institution - 0046

    Trento, 38100, Italy

  • Local Institution - 0047

    Rotterdam, 3015 CE, Netherlands

  • Local Institution - 0048

    Tromsø, 9019, Norway

  • Local Institution - 0049

    Trondheim, 7006, Norway

  • Local Institution - 0050

    Lima, LIMA 14, Peru

  • Local Institution - 0051

    Moscow, 115522, Russia

  • Local Institution - 0052

    Saratov, 410054, Russia

  • Local Institution - 0053

    Saint Petersburg, 194100, Russia

  • Local Institution - 0055

    Jeddah, 21159, Saudi Arabia

  • Local Institution - 0056

    Bayamón, PR 960, Puerto Rico

  • Local Institution - 0057

    Panorama, Cape Town, Western Cape, 7500, South Africa

  • Local Institution - 0058

    Pretoria, 0084, South Africa

  • Local Institution - 0059

    Cincinnati, Ohio, 45229, United States

  • Local Institution - 0060

    Little Rock, Arkansas, 72202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.